Medical News Summary: Drug company receives FDA approval for high dose GERD treatment


About: Drug company receives FDA approval for high dose GERD treatment
Date: 22 December 2004
Source: Businesswire
Medical News Summary (summary of medical news story as reported by Businesswire): The pharmaceutical company Santarus has received FDA approval for the first and only immediate-release oral proton pump inhibitor to be used by critically ill patients. It reduces the risk of upper gastrointestinal bleeding and provides short term treatment for active benign gastric ulcers. The product is called ZEGERID. The product allows for an immediate, higher dose product. Lower dose ZEGERID has already been approved for use as a short term treatment for active duodenal ulcers, heartburn, erosive esophagitis and other gastroesophageal reflux disease symptoms. The most common side effects associated with the drug include headache, diarrhea and abdominal pain. The medication should not be taken by people who are trying to restrict their sodium intake and by people who suffer from metabolic alkalosis and hypocalcemia.
Related Disease Topics: GERD, Gastrointestinal esophageal reflux disease, Upper gastrointestinal bleeding, Benign gastric ulcer, Ulcer, Duodenal ulcer, Heartburn, Erosive esophagitis, Metabolic alkalosis, Hypocalcemia
Related Symptom Topics: Headache, diarrhea, abdominal pain

Related Medical News Channels: This medical news summary article refers to the following medical channel categories:

Medical Tools & Articles:

Next articles:

Medical Articles:
CureResearch.comTM Copyright © 2010 Health Grades, Inc. All rights reserved.
Home | Contents | Search | Site Map | Feedback | Contact Us | Terms of Use | Privacy Policy | About Us | Advertise